Gyre Therapeutics (GYRE) Revenue Growth (3y) (2013 - 2026)
Powered by 
Analysis
Gyre Therapeutics (GYRE) Revenue Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 10.17% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 10.76% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 77.85% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -25.02% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 42.02% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 59.40% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 7.80% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 76.62% |
| 10 | Gyre Therapeutics | 691.38 Mn | 633.98 Mn | 26.90 Mn | -0.26% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -0.26% |
| Mar 31, 2026 | -3.33% |
| Dec 31, 2025 | -28.44% |
| Mar 31, 2025 | 202.86% |
| Dec 31, 2024 | 125.21% |
| Sep 30, 2024 | 122.98% |
| Jun 30, 2024 | 181.40% |
| Mar 31, 2024 | 164.58% |
| Dec 31, 2023 | 137.32% |
| Sep 30, 2023 | 229.83% |
| Jun 30, 2023 | 160.56% |
| Mar 31, 2023 | 15.06% |
| Mar 31, 2021 | 525.31% |
| Dec 31, 2020 | 85.54% |
| Sep 30, 2020 | 41.08% |
| Jun 30, 2020 | 146.28% |
| Mar 31, 2020 | 292.34% |
| Mar 31, 2018 | -79.25% |
| Dec 31, 2017 | -22.07% |
| Sep 30, 2017 | -16.54% |